Stealth BioTherapeutics Corp

NasdaqGM:MITO Stock Report

Market Cap: US$23.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stealth BioTherapeutics Future Growth

Future criteria checks 0/6

Key information

3.4%

Earnings growth rate

95.08%

EPS growth rate

Biotechs earnings growth22.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updatedn/a

Recent future growth updates

Recent updates

Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company

Sep 30

Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private

Aug 01

Stealth BioTherapeutics: A Net-Net Biopharma Going Private

Jul 26

Stealth BioTherapeutics receives Nasdaq non-compliance receipt

Jul 11

Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year

Dec 31
Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year

Earnings and Revenue Growth Forecasts

NasdaqGM:MITO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2024N/A-48N/AN/A1
12/31/2023N/A-48N/AN/A2
12/31/2022N/A-45N/AN/A2
12/31/2021N/A-53-45-45N/A
9/30/2021N/A-51N/AN/AN/A
6/30/2021N/A-56-44-44N/A
3/31/2021N/A-50N/AN/AN/A
12/31/2020N/A-57-54-54N/A
9/30/202021-35-39-38N/A
6/30/202021-41N/AN/AN/A
3/31/202021-44N/AN/AN/A
12/31/201921-72-48-48N/A
9/30/2019N/A-102-75-74N/A
6/30/2019N/A-108N/AN/AN/A
3/31/2019N/A-120N/AN/AN/A
12/31/2018N/A-97-72-72N/A
9/30/2018N/A-92-69-69N/A
12/31/2017N/A-83-70-70N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MITO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MITO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MITO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MITO's revenue is forecast to grow faster than the US market.

High Growth Revenue: MITO is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MITO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/16 07:08
End of Day Share Price 2022/11/15 00:00
Earnings2021/12/31
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Stealth BioTherapeutics Corp is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Charles DuncanCantor Fitzgerald & Co.
Joshua SchimmerEvercore ISI